Itraconazole and fluconazole are oral antifungal drugs, which have a wide spectrum antifungal activity and better efficacy than the older drugs. However, both drugs have been associated with hepatotoxicity in susceptible patients. The mechanism of antifungal drug-induced hepatotoxicity is largely unknown. Therefore, the aim of this present study was to investigate and compare the hepatotoxicity induced by these drugs in vivo. Rats were treated intraperitoneally with itraconazole or fluconazole either single (0, 10, l00 and 200 mg/kg) or subchronic (0, 10, 50 and loo mg/kg per day for 14 days) doses. Plasma and liver samples were taken at the end of the study. A statistically significant and dose dependent increase of plasma alanine aminotransferase (ALT) and alkaline phosphatase (ALP) activities were detected in the subchronic itraconazole-treated group. In addition, dose-dependent hepatocellular necrosis, degeneration of periacinar and mizonal hepatocytes, bile duct hyperplasia and biliary cirrhosis and giant cell granuloma were observed histologically in the same group. Interestingly, fluconazole treated rats had no significant increase in transaminases for both single and subchronic groups. In the subchronic fluconazole treated rats, only mild degenerative changes of centrilobular hepatocytes were observed. These results demonstrated that itraconazole was a more potent hepatotoxicant than fluconazole in vivo in rats. Human & Experimental Toxicology (2004) 23, 519-525 
Introduction
The azole antifungal agents are a major development in the therapy and management of superficial and systemic mycoses. These classes of drugs consist of two groups: the imidazoles (ketoconazole and miconazole) and the triazoles (itraconazole and fluconazole). The triazole antifungal agents were approved for use in the early 1990s in the USA.'
They have a wide spectrum of activity against dermatophytes (Trichophyton, Epiderophyton and Microsporum spp.), moulds (Aspergillus spp.) and yeast (Candidia spp. and Cryptococcus neoformans).' *Correspondence: Dr. Nhareet Somchit, Pharmacology and Toxicology Unit, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 Serdang, Selangor, Malaysia E-mail: nhareet@medic.upm.edu.my Itraconazole and fluconazole act primarily by inhibiting biosynthesis of ergosterol, which is an essential component of fungal cell membranes. 23 The drugs bind more avidly to fungal cytochrome P450 preventing the conversion of lanosterol to ergosterol, which leads to abnormalities in cell membrane activity and membrane-bound enzyme activities causing fungal cell death.3 Other postulated mechanism of fungicidal action of the triazoles is the inhibition of cytochrome c oxidase and peroxidative enzymes leading to disruption of the fungal cell phospholipid bilayer membrane. 2 The triazoles are thought to have greater antifungal potency, lower toxicity and a wider antifungal spectrum activity than the imidazoles.14 However, there have been several reports that itraconazole and fluconazole induced adverse drug reactions. One study has documented that over 15 
Results
There was a reduction in the body weight of rats in the 100 mg/kg per day subchronic itraconazole group (Table 1) . These rats were depressed and reluctant to move prior to sacrifice. In the other dosing groups, body weight was maintained or increased approximately 2% daily (Table 1) . There were no changes in body weights in the single dose study (data not shown). Liver weights in the lo mg/kg per day subchronic itraconazole treated rats were significantly higher than the controls (Table 2) . No significant changes were observed in the other dosing groups (Table 1) . Plasma ALP and ALT were both significantly increased in the 100 mg/kg per day subchronic itraconazole group (Table 3 ). In the other groups (subchronic and single doses), these plasma parameters were not significantly different when compared to controls. Fluconazole did not have any effects upon the body or liver weight (Tables 1 and  2 ) and plasma enzymes of rats (Table 3) .
Histological examinations demonstrated that subchronic itraconazole treatment resulted in a dosedependent severe degeneration of centrilobular and midzonal regions ( Figure 1A and 1B), cloudy swelling and apoptosis were also observed throughout the liver parenchyma. Bile ductule hyperplasia and biliary cirrhosis ( Figure 1C) were observed in the livers of the high dose group (100 mg itraconazole/kg per day). Focal necrosis and severe infiltration of neutrophils were also detected in the livers of these rats. Granulomas with detection of giant cells ( Figure 1D ) were detected in livers of rats in this group. The 10 mg/kg per day itraconazole treated rats showed no hepatocellular damage (data not shown). Interestingly, fluconazole treated rats (loomg/kg per day for 14 days) showed only mild hepatocyte degeneration in the centrilobular region of the liver parenchyma ( Figure 1E ). The 10 and 50 mg/kg per day fluconazole treated rats revealed normal liver histology (data not shown). The controls ( Figure 1F) showed normal liver histology. Single doses at 200 mg/kg fluconazole or 100 and 200 mg/kg itraconazole revealed mild hepatocellular degeneration (Figure 2A and 2B). Rats having received 10 and 100 mg/kg fluconazole and 100 mg/kg itraconazole revealed normal liver histology (data not shown). The control liver sections were normal ( Figure 2C ). The summary for these histopathological findings is presented in Table 4 .
Discussion
This work revealed that repeated daily treatment by itraconazole induced elevated plasma ALT and ALP activities, severe hepatocellular necrosis and significant increase of liver weight. However, fluconazole only resulted in mild degeneration of hepatocytes with no alteration in plasma activities of liver enzymes.
Both itraconazole and fluconazole are synthetic antifungal agents that are useful for mycoses.1 In animal and in vitro studies, these drugs were highly active against wide varieties of fungi with improved pharmacokinetics. They have a prolonged half-life, increased drug availability at sites of infection and they are metabolically stable molecules when compared to the previous azoles.3 '17 Clinically, both these drugs have been very effective for numerous superficial and systemic fungal diseases.5 The toxicity of itraconazole and fluconazole therapy has been originally reported to be minimal. 23 Itraconazole is the drug of choice for crytococcal meningitis and disseminated histoplasmosis. However, two of 50 patients with crytococcal meningitis24 and three of 46 patients with disseminated histoplasmosis25 developed hepatotoxicity and therapy was discontinued. It has been concluded that although itraconazole is well tolerated, clinicians should be alert and be vigilant for drug interaction and possible hepatotoxicity induced by itraconazole. Therefore, it may be advisable to monitor liver enzymes in patients who are on long-term itraconazole therapy.
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